

Novartis selling flu vaccine unit to CSL for \$275M

October 27 2014

Australian drugmaker CSL Ltd. said Monday it will buy Novartis' flu vaccine business for \$275 million.

CSL Ltd. said the [deal](#) will make it the second-largest flu vaccine maker in the world. The company said the Novartis business had \$527 million in revenue in 2013 and said its combined revenue could reach \$1 billion a year in three to five years.

Novartis flu vaccines include Flucelvax, Fluvirin and Fluvad. The Switzerland-based company, which expects to ship about 60 million doses worldwide of its seasonal influenza vaccines for the 2014-2015 season, reported \$57.92 billion in total revenue in 2013.

Shares of Novartis AG picked up 24 cents to \$90.39 in midday trading.

© 2014 The Associated Press. All rights reserved.

Citation: Novartis selling flu vaccine unit to CSL for \$275M (2014, October 27) retrieved 3 May 2024 from <https://medicalxpress.com/news/2014-10-novartis-flu-vaccine-csl-275m.html>

| |
|--|
| <p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p> |
|--|